High-Dose Cytarabine Induction for Acute Myeloid Leukemia

To the Editor:
In a recent article, Bishop et al' state that high-dose cytarabine has not previously been used as induction for untreated acute myeloid leukemia (AML). In fact, high-dose cytarabine has been used by itself: with am~acrine,~ and with daunorubicin4 in this role. Additionally, doses of cytarabine significantly above those considered standard had previously been used by other groups for initial induction' with daunorubicin.
The report by Bishop et all builds on these previous experiences and clearly supports a role for high-dose cytarabine as initial therapy, as we and other groups have reported.
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Vaughan WP, Karp JE, Burke PJ: Two-cycle timed-sequential chemotherapy for adult acute nonlymphocytic leukemia. Blood 64: 975, 1984 Response: Induction Endpoints in AML Shepherd et al are quite right. High-dose cytarabine has been used in a number of single-ann studies in the induction therapy of AML. However, our report is one of the first published papers of a phase 111 randomized study of high-dose cytarabine in the induction of de novo AML.' The South-West Oncology Group (SWOG) is soon to publish its randomised study of high-dose cytarabine induction with similar results. ' We believe the distinction between phase 111 randomized and phase 11 single ann studies is important for the usual reasons that large randomized comparisons are the appropriate clinical trial methodology to avoid bias when comparing treatments. However, in addition, single-arm studies reporting high response rates in AML are difficult to interpret. A number of recent randomized trials of AML induction intensified with high-dose cytarabine'.* or etopohave shown no difference in complete remission (CR) rate but clinically important, statistically significant differences in remission duration, relapse-free survival, or survival.
An explanation for this discrepancy may be that most modem standard-dose induction chemotherapy is probably as successful as more intensive regimens in reducing marrow blasts to less than 5%. CR as measured by blasts in bone marrow on morphology (CR-BM) fails to detect clinically important residual disease in about 50% of patients who subsequently relapse. Thus, when reporting clinical trials it would be useful to routinely report cytogenetic CR (CR-C) or loss of a molecular marker (CR-M) to better understand the likely burden of residual subclinical disease.
The important observation that intensified induction therapy prolongs remission may also provide a useful clinical tool to evaluate a number of new induction therapies, all of which could produce high rates of CR. We have recently defined a new endpoint, time to failure, for evaluating induction treatment. This endpoint incorporates early deaths, failure to achieve CR, relapse after CR, and death in CR.5 This endpoint allows the individual types of failure to be studied as competing risks and is a valuable method for comparing induction regimens.
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